BeOne Medicines AG
ONCHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeBeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The $32.37B market capitalization puts ONC squarely in large-cap range for its industry. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Market Cap
$32.37B
Beta
0.49
P/E (TTM)
71.89
P/E (Fwd)
32.40
EPS (TTM)
$4.34
EPS (Fwd)
$9.63
ROE
12.4%
ROA
6.0%
Cash
$4.79B
Total Debt
$2.05B
Free CF
$844.6M
52W Change
5.9%
Annual Financials
Cash vs Debt
BeOne Medicines AG holds $4.79B in cash against $2.05B in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $844.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 12.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.42B (2022) to $5.34B (2025), reflecting a 277% increase over the period.
ONC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, ONC carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BeOne Medicines AG's trajectory.